What Researchers Did
Researchers conducted a systematic review to outline the historical development, recent advances, therapeutic mechanisms, and clinical outcomes of hyperbaric oxygen therapy in cardiovascular diseases.
What They Found
Hyperbaric oxygen therapy (HBOT) enhances oxygen delivery, promotes angiogenesis, and suppresses oxidative stress, inflammation, and cardiomyocyte apoptosis in cardiovascular diseases. It markedly improves left ventricular ejection fraction in acute myocardial infarction, facilitates myocardial repair in heart failure, reduces arrhythmia frequency, and mitigates neurological complications post-ablation.
What This Means for Canadian Patients
Hyperbaric oxygen therapy shows promise as an additional treatment strategy for Canadian patients suffering from various cardiovascular diseases. This could potentially lead to improved cardiac function, reduced complications after heart attacks or surgery, and better management of arrhythmias.
Canadian Relevance
This review has no direct Canadian connection as it was not conducted by Canadian researchers or in Canada.
Study Limitations
The abstract indicates that despite promising applications, the widespread adoption of hyperbaric oxygen therapy remains hindered, suggesting practical or evidence-based limitations.